The latest UDMI aims to align classifications with pathology and clinical practice, bringing numerous changes to the 2018 ...

The data “give you pause” when considering closure, especially for women who can tolerate DOACs, Christine Albert says.

Asymptomatic patients will now be covered and more flexibility has been given to heart teams for individualizing patient care ...

SHASTA-3/4 trial data show plozasiran, like olezarsen, can drastically lower triglycerides and the risk of acute pancreatitis ...

It’s unlikely a lipid-lowering agent can directly reduce infection or malignancy, but some argue it could stop a domino ...

Multiple US health systems have been awaiting the authorization before taking the Queen of Hearts platform live.

Doing TAVI first was noninferior to a PCI-first strategy, with experts pointing out that each timing has its advantages.

Mirvat Alasnag talks with host Yael L. Maxwell about the need to prove herself, social media, and partnerships with patients.

It’s unclear if individual parts of the intervention or the integrated approach itself contributed to improvement over usual ...

Novartis announced that the phase III CV outcomes trial did not meet its primary endpoint, raising doubts over Lp(a)’s role.

Larger trials with longer follow-up are still needed to cement CSP as an alternative to biventricular pacing, experts say.